The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isThe entire human record is one phase I study, described inside a single paper by the people developing it (Ivachtchenko 2016).
- What to watchDaytime drowsiness that affects driving.
How Aviandr works
The catalog calls this a 5-HT6 antagonist. Its own developers' paper says 5-HT6 is not its strongest target, and not its second or third either.
The histamine number is the one a buyer will actually feel. An H1 affinity of 0.58 nM is in the range of drugs prescribed as sedating antihistamines, and central H1 blockade is the standard pharmacological explanation for daytime sleepiness and weight gain in several psychiatric drug classes. Anyone taking this and reporting that it calms them down is describing an effect that the affinity table predicts without reference to serotonin at all.
The published affinities are 5-HT7 at Ki 153 pM, histamine H1 at 0.58 nM, adrenergic alpha-2A, 2B and 2C at 0.41 to 3.6 nM, and only then 5-HT6, 5-HT2A and 5-HT2C at 1.2 to 2.0 nM. The receptor the product is named for is roughly eight to thirteen times weaker than its strongest target and is outranked by an antihistamine site and three adrenergic ones. There is no selective window.
- Oral
On the goal map: Glutamatergic & synaptic plasticity (Focus, memory & cognition)
Research on Aviandr7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: One phase I tolerability study, described inside a single paper by its developers. No efficacy trial in patients has been published in the ten years since.
Human clinical evidence
The entire human record is one phase I study, described inside a single paper by the people developing it (Ivachtchenko 2016). The ceiling of the only tested range.
No efficacy trial in patients has been published in the ten years since, in any of the five indications the 2016 paper proposed.
Correlative data
The mechanism it is sold on has been tested at scale and failed twice. Neither significant (Lang 2021). Masupirdine in 564 randomized patients over 26 weeks was also non-significant on ADAS-Cog 11 (Nirogi 2022).
A class failure is not proof a particular molecule fails, and the reviews still treat 5-HT6 as an open target (Nirogi 2023, Chagraoui 2025). What the trials establish is that the hypothesis has been given 1,879 randomized patients and returned nothing on the endpoints it was built to move.
How the mechanism reads
The catalog calls it a 5-HT6 antagonist and its own developers' binding data says otherwise: 5-HT7 at Ki 153 pM, histamine H1 at 0.58 nM, adrenergic alpha-2A/2B/2C at 0.41-3.6 nM, and only then 5-HT6, 5-HT2A and 5-HT2C at 1.2-2.0 nM.
MechanisticBecause receptors fill in order of affinity. There is no window in which this behaves as a selective 5-HT6 drug.
MechanisticPredicted downside: an H1 affinity of 0.58 nM is sedating-antihistamine territory, which predicts daytime drowsiness and additive effect with alcohol — the opposite of a cognitive enhancer. The paper reports affinity only and never states whether the compound is an agonist or antagonist at the alpha-2 sites, so the direction of its autonomic effect is genuinely unknown.
Mechanistic
Sources
- Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. Journal of Alzheimer's Disease 2016 · PMID 27232215
- Lang FM, Mo Y, Sabbagh M, et al. Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: a randomized, placebo-controlled, phase 3 clinical trial (MINDSET). Alzheimer's & Dementia: Translational Research & Clinical Interventions 2021 · PMID 34095437
- Nirogi R, Ieni J, Goyal VK, et al. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: a randomized, double-blind, phase 2, proof-of-concept study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2022 · PMID 35662833
- Nirogi R. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders. Biomolecules 2023 · PMID 36830678
- Chagraoui A. 5-HT6 receptors: contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders. Dialogues in Clinical Neuroscience 2025 · PMID 40347153
Aviandr safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Taking an antidepressant or other serotonergic drug, because it binds several serotonin receptors.
- Taking sedating antihistamines or sleep aids, as strong histamine H1 binding adds sedation.
- Arrhythmia or long QT, where nothing has been measured.
- Liver disease, since its metabolism is uncharacterized.
- Pregnancy or under 18, where this multi-target drug has no safety work.
What’s expected
- Sedation or calm from histamine H1 and 5-HT7 binding.
- Possible appetite and weight rise, the usual consequence of H1 blockade.
- Cognitive effects that no regulator has reviewed.
Watch for
- Daytime drowsiness that affects driving.
- A racing pulse or blood pressure rise from alpha-2 receptor binding.
- Mood swings or vivid dreams.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: baseline liver and kidney function for an unapproved drug.
- HbA1c: H1 and 5-HT2C binding can push appetite and glucose.
- Lipid Panel: weight gain from H1 blockade shows here first.
Sold as a 5-HT6 antagonist, but published binding is strongest at 5-HT7, H1 and alpha-2 receptors; profile follows those targets. PMID 27232215
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Aviandr FAQ4 common questions
- Is Aviandr approved for human use?
- No. Aviandr is a research compound.
- What is Aviandr researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; HbA1c; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Aviandr: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



